Wnt/β-catenin signaling inhibitors in current clinical trials
| Drug | Target | Cancer type | Phase | Clinicaltrials. Govidentifier |
|---|---|---|---|---|
| LGK974 | PORCN | Melanoma, breast cancer and pancreatic CA | I | NCT01351103 |
| ETC-1922159 | PORCN | Solid tumors | I | NCT02521844 |
| CGX1321 | PORCN | Colorectal adenocarcinoma Gastric adenocarcinoma Pancreatic adenocarcinoma Bile duct carcinoma Hepatocellular carcinoma Esophageal carcinoma Gastrointestinal cancer | I | NCT03507998 |
| DKN-01 | DKK1 | Hepatocellular carcinoma | I/II | NCT03645980 |
| Niclosamide | Axin1 | Metachronous or synchronous metastases of a colorectal cancer progressing after therapy | II | NCT02519582 |
| PRI-724 | β-Catenin | Advanced pancreatic cancer Metastatic pancreatic cancer Pancreatic adenocarcinoma | I | NCT01764477 |
| OMP-18R5 (Vantictumab) | Frizzled receptor | Breast cancer | Ib | NCT01973309 |
| OMP-54F28 (Ipafricept) | Frizzled family receptor 8 | Solid tumors | I | NCT01608867 |
| SM08502 | Wnt pathway related-gene expression | Solid tumors | I | NCT03355066 |